We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Monday broker round-up UPDATE

Mon, 04th Nov 2013 08:07

Aggreko: Cantor Fitzgerald reduces target price from 2200p to 1700p downgrading to hold.Anglo American: Alphavalue upgrades from add to buy with a target price of 1801.3p.APR Energy: Cantor Fitzgerald raises target price from 670p to 1000p, but still recommends selling.Astra Zeneca: UBS reduces target price from 3600p to 3400p and downgrades from buy to neutral.British Sky Broadcasting: Westhouse Securities downgrades to neutral with a target price of 985p.BT Group: Alphavalue downgrades from reduce to sell with a target price of 323.8p. HSBC ups target price from 220p to 440p upgrading to overweight.Centrica: Investec lowers target price from 375p to 325p downgrading from add to reduce.e2v technologies: Investec shifts target price from 205p to 210p and keeps a buy recommendation.First Group: Deutsche Bank cuts target price from 154p to 128p retaining a hold recommendation.Glencore Xstrata: Goldman Sachs shifts target price from 360p to 355p and maintains a neutral rating.Go-Ahead Group: Deutsche Bank increases target price from 1500p to 1640p and maintains a buy recommendation.Gooch & Housego: FinnCap initiates with a target price of 680p and a buy recommendation.Imagination Technologies: UBS cuts target price from 260p to 240p and retains a sell recommendation.International Consolidated Airline Group: Deutsche Bank ups target price from 360p to 400p retaining a buy recommendation.Meggitt: UBS moves target price from 540p to 530p and stays with its neutral rating.Mothercare: UBS cuts target price from 460p to 420p, while upgrading from sell to neutral.National Express: Deutsche Bank raises target price from 210p to 240p and reiterates its hold recommendation.National Grid: Alphavalue downgrades from add to reduce with a target price of 786.5p.Partnership Assurance Group: Canaccord Genuity initiates with a target price of 450p and a hold recommendation.Polar Capital Holdings: Canaccord Genuity downgrades from buy to hold with a target price of 550p.Redrow: UBS moves target price from 290p to 300p and reiterates a buy recommendation.Royal Bank of Scotland: UBS lowers target price from 365p to 350p and maintains a neutral rating. Barclays reduces target price from 400p to 380p maintaining an overweight rating.Royal Dutch Shell: Liberum Capital cuts target price from 2200p to 2140p, while its hold recommendation remains unchanged.Smith & Nephew: Jefferies moves target price from 890p to 900p and keeps a buy recommendation.SSE: Investec reduces target price from 1475p to 1325p downgrading from add to reduce.Stagecoach Group: Deutsche Bank takes target price from 350p to 365p and leaves its buy recommendation unchanged.Steppe Cement: Westhouse Securities moves target price from 46p to 54p and retains a buy recommendation.Weir Group: Investec places both its target price (prev.: 2610p) and its buy recommendation under review. Numis downgrades to add with a target price of 2500p.

Related Shares

More News
Today 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Today 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsort...

Today 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out...

2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for pr...

2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood canc...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.